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Background: Vaccination against tumor-associated antigens is one promising approach to immunotherapy against
malignant gliomas. While previous vaccine efforts have focused exclusively on HLA class I-restricted peptides, class
II-restricted peptides are necessary to induce CD4+ helper T cells and sustain effective anti-tumor immunity. In this
report we investigated the ability of five candidate peptide epitopes derived from glioma-associated antigens
MAGE and IL-13 receptor α2 to detect and characterize CD4+ helper T cell responses in the peripheral blood of
patients with malignant gliomas.
Methods: Primary T cell responses were determined by stimulating freshly isolated PBMCs from patients with
primary glioblastoma (GBM) (n = 8), recurrent GBM (n = 5), meningioma (n = 7), and healthy controls (n = 6) with
each candidate peptide, as well as anti-CD3 monoclonal antibody (mAb) and an immunodominant peptide epitope
derived from myelin basic protein (MBP) serving as positive and negative controls, respectively. ELISA was used to
measure IFN-γ and IL-5 levels, and the ratio of IFN-γ/IL-5 was used to determine whether the response had a
predominant Th1 or Th2 bias.
Results: We demonstrate that novel HLA Class-II restricted MAGE-A3 and IL-13Rα2 peptides can detect T cell
responses in patients with GBMs as well as in healthy subjects. Stimulation with a variety of peptide antigens
over-expressed by gliomas is associated with a profound reduction in the IFN-γ/IL-5 ratio in GBM patients relative to
healthy subjects. This bias is more pronounced in patients with recurrent GBMs.
Conclusions: Therapeutic vaccine strategies to shift tumor antigen-specific T cell response to a more
immunostimulatory Th1 bias may be needed for immunotherapeutic trials to be more successful clinically.Background
Passionate debate for over 100 years [1] has surrounded
the concept that host immunity can protect against tumor
development without external therapeutic intervention.
This concept – cancer immunosurveillance –named and
further developed in the late 1950s by Burnet and Thomas
[2,3] was more recently refined by Schreiber and colleagues
to reflect the additional influence host immunity has in
shaping the immunological phenotype of tumor cells, a
concept called cancer immunoediting [4]. A large body
of animal and human data now provide convincing sup-
port for the ability of host immunity to suppress tumor
development [5].
Nevertheless, cancer vaccines have thus far over-
whelmingly failed to induce objective clinical responses* Correspondence: deanderson.phd@gmail.com
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reproduction in any medium, provided the or[6]. There are many potential explanations for the lack
of efficacious therapeutic cancer vaccines, including the
challenges of inducing potent immunity given the poor
inherent immunogenicity of most tumor-associated anti-
gens, the presence of regulatory T cell populations, and
the immunosuppressive tumor environments in which
tumor-specific T cells are needed to exert their function
[7,8]. Additionally, in spite of studies demonstrating the
importance of T helper cells in sustaining effective CTL
responses [9,10], early cancer vaccines have been overly
focused on assessing and improving tumor-specific CTL
responses with comparatively little attention paid to T
helper cell responses [11,12]. Peptide-based cancer
vaccines in particular have overwhelmingly relied on only
one or a few HLA class I-restricted cytotoxic T lymphocyte
(CTL) epitopes typically without inclusion of any HLA
class II-restricted T helper cell epitopes [13,14].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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epitopes derived from MAGE family and interleukin-13
receptor α2 (IL-13Rα2) antigens that were designed for
recognition by class II-restricted T helper cells. We
tested the ability of our selected candidate peptides to
induce T cell responses in peripheral blood from patients
with GBMs by measuring IFN-γ and IL-5 as type 1 and
2 T helper cell cytokines, respectively. Our results dem-
onstrate that our candidate peptides detected CD4+ T
helper cell responses in patients with GBMs as well as
healthy subjects. While helper T cell responses in
healthy subjects had a clear Th1 bias, T cell responses in
patients with GBMs demonstrated a markedly Th2-
skewed response, which was even more pronounced in
patients with recurrent GBMs. These findings suggest
that future vaccination strategies that stimulate both
class I and class II restricted T cells, as well as reverse
the profound Th2 skewing, may be needed to have
significant clinical efficacy in patients with GBMs.Methods
Peptides
All peptides were synthesized using standard FMOC
chemistry to 95% purity (New England Peptide Company).
All peptides were at least 15 amino acids in length. The




FILILV); IL-13Rα2351-365 (ILILVIFVTGLLLRK); MBP85-99
(ENPVVHFFKNIVTPR). HLA class II alleles predicted to
bind the peptides were determined using ProPred HLA
class II binding algorithm [15], summarized in Table 1. All
peptides were predicted to be very promiscuous, binding to
multiple (up to 9 in several cases) alleles. The validity of the
predictions is supported by experimental data for the
MBP85-99 peptide, which has been shown to bind to both
the DRB1*04 and *15 alleles as predicted [16].Table 1 Predicted HLA Class II Binding Alleles for the
peptides used in this study
Epitope Predicted HLA Class II Binding Alleles
MAGE-A3112-127 DRB1*04, *08, *11, *13, DRB5*01
MAGE-A3121-136 DRB1*04, *07, *08, *11, *13, *15, DRB5*01
MAGE-A3143-160 DRB1*01, *03, *04, *07, *08, *11, *13, *15, DRB5*01
IL-13Ra2341-355 DRB1*01, *03, *04, *07, *08, *11, *13, *15, DRB5*01
IL-13Ra2351-365 DRB1*01, *03, *04, *07, *08, *11, *13, *15, DRB5*01
MBP85-99 DRB1*01, *03, *04, *08, *11, *13, *15
Putative HLA-DR binding was determined using the ProPred MHC Class-II
binding peptide prediction server, and emphasizes the promiscuous binding
of the MAGE-A3 and IL-13Rα2 peptides used in this study.Isolation of PBMCs
Twenty-five mL of blood from patients or healthy
subjects was obtained under an IRB-approved protocol.
All samples of blood from patients were taken at the
time of surgery. Ages of the patients ranged from 48 to
76 among patients with primary GBMs (median age 55),
from 41 to 69 among patients with recurrent GBMs
(median age 52), and from 40 to 73 among patients with
meningiomas (median age 62). A greater number of men
had primary or recurrent GBMs (6 of 8 patients and 5 of
6 patients, respectively), while more women than men
had meningiomas (5 of 8 patients). Primary and recurrent
GBMs were located in temporal, parietal, and frontal lobes
with comparable frequencies. All tumor-bearing patients
received similar doses of steroids and anti-epileptic
medications at the time of tumor debulking surgery
prior to obtaining peripheral blood for these studies. T
cell responses in patients with meningiomas controlled
for influences of steroids on antigen responsiveness and
cytokine balance. Tumor tissue was independently con-
firmed in all cases by formal pathological analysis. PBMCs
were purified from heparinized blood by density gradient
centrifugation using Ficoll-Hypaque (GE Healthcare
Biosciences), and cells were then washed with PBS and
viable cells quantified by trypan-blue staining.
PBMC culture with peptides
Freshly isolated PBMCs were plated at 2 × 105 cells/well
in 200 μl of serum-free X-VIVO15 (X15) media (Lonza)
in 96-well round-bottom cell culture plates. Candidate
peptides, in addition to a negative control peptide derived
from MBP were added at a concentration of 10 μg/mL and
anti-CD3 mAb was added at a concentration of 1 μg/mL.
Six T cell cultures were established for each condition in
each subject, and 100 IU/ml of IL-2 was added on the fol-
lowing day. Plates were incubated at 37°C and 5% CO2 for
14 days, with media changed as needed, and the super-
natant was harvested to evaluate T cell responses (cyto-
kines) induced by each condition using ELISA. In a limited
number (n = 3) of patients, we assessed cytokine production
after both 7 and 14 days. Tumor-specific responses were
apparent at day 7, and the frequency of positive responses
did not change significantly at day 14, but the cytokine
values did increase significantly (data not shown). An IFN-
ELISPOT assay was performed as previously described
[17].
Cytokine measurement
To detect T helper cell responses directed against the
candidate peptides, IFN-γ and IL-5 were measured by
ELISA using commercially available kits supplied by BD
bioscience. IFN-γ was used as a prototypic Th1 cytokine
and IL-5 was chosen as a prototypic cytokine released by
Th2 cells because unlike IL-4 there would be no
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culture conditions [18]. The Th2-associated transcription
factor GATA-3 directly binds and regulates both the IL-4
and IL-5 gene promoters [19] and a positive correlation
has been reported among GATA-3, IL-4, and IL-5 gene
expression during human T cell differentiation [20], pro-
viding further support for analysis of IL-5 as a representa-
tive Th2 cytokine. Initial experiments also examined the
secretion of IL-10 in response to peptide stimulation,
which was not detected. Flat-bottom microtiter plates
(Immulon) were coated with primary antibody (IFN-γ or
IL-5) diluted 1:1000 in NaHCO3 and incubated overnight
at 4°C. Coating solution was then removed, plates blocked
with PBS + 10%FBS at 25°C for 2 hours, rinsed 3 times
with diluted wash buffer (dH20, Tween 20, PBS 20X), and
standards were then added in duplicate at 0, 62.5, 125, 250,
500, 1000, 2000, and 4000 pg/mL (diluted in X15 media).
Supernatants (50 μl/well) from T cell assays were then
added to wells. Plates were incubated for 2 hours at 25°C
and subsequently rinsed 3 times. Wells were then coated
with a secondary biotinylated antibody diluted 1:1000 in
PBS + 1%FBS and incubated for 1 hour at 25°C. Plates were
again rinsed 3 times and avidin-peroxidase diluted 1:1000
in PBS+10%FBS was added and incubated for another
1hour. After rinsing 6 times, TMB (tetramethylbenzidine)
(BD biosciences) was added to wells, which were allowed
to develop. The reaction was stopped by adding 50 μL of
sulfuric acid and absorbance was measured at 455 nm by
an ELISA plate reader (BIO-RADR). A standard curve was
generated by plotting absorbance against each reference
standard, and sample concentrations were extrapolated
from this curve. Appropriate statistical tests and analyses
based on our data were determined using Prism 5.0
(GraphPad software).
Results
Global T cell responses
Six primary T cell cultures were established from each
patient against all stimuli. Anti-CD3 mAb was used to
stimulate and expand T cells to confirm T cell viability
and to examine global, nonspecific T cell cytokine
responses among the different cohorts. Relative to
healthy subjects, anti-CD3 mAb-induced IFN-γ levels in
patients with GBMs (primary and recurrent) and meningi-
omas were modestly lower (Figure 1a). More strikingly,
anti-CD3 mAb stimulation uniquely induced secretion of
high amounts of IL-5 from patients with recurrent GBMs
(P < 0.0001). A recent clinical trial examined the IFN-γ/IL-5
ratio after polyclonal stimulation of PBMCs in patients with
metastatic melanoma treated with immunomodulators
given to restore the Th1/Th2 balance [21], and we
performed a similar analysis of our data (Figure 1b). The
IFN-γ/IL-5 ratios in both primary GBM patients (geometric
mean 3.7) and recurrent GBMs (geometric mean 0.9) weresignificantly lower than those in healthy subjects (geometric
mean 16.0) and meningioma patients (geometric mean
10.0) (p<0.001). This antigen-nonspecific bias towards a
Th2 response in patients with primary and recurrent GBMs
is consistent with past reports [22-25]. There was no signifi-
cant difference in the global IFN-γ/IL-5 ratio between
healthy subjects and meningioma patients, indicating that
neither treatment with steroids or antiepileptic medications
nor the simple presence of a CNS tumor were responsible
for the deviation in global T cell responses.
Responses to HLA Class II-restricted peptide stimulation
Both glial cells and melanocytes derive from neural
ectoderm [26] and several studies have demonstrated
that melanoma-associated tumor antigens are also
expressed by gliomas, including MAGE-A3 [27-29]. Like
MAGE-A3, IL-13Rα2 is a cancer testes antigen that is
over-expressed in gliomas [30,31]. In trying to identify
novel glioma-associated HLA class II-restricted T helper
cell epitopes, we hypothesized that epitopes identified in
patients with melanoma may similarly be expressed by
patients with gliomas. Two such epitopes with homology
to MAGE-A3 were identified [32-34], which we modified
to incorporate adjacent HLA class I-restricted CTL epi-
topes [35-38] as well as several amino acid substitutions.
The amino acid substitutions altered the hydrophobicity of
the peptides but not their charge (Ala to Asp, Leu to Arg)
and potentially their secondary structure (Pro to Leu).
Similarly, two overlapping 15mer IL-13Rα2 epitopes were
identified, one of which was modified to incorporate a CTL
epitope [39]. The five epitopes used in this study in relation
to previously described epitopes are depicted in Table 2.
Measurement of antigen-specific T cell responses in
the peripheral blood in humans differs depending on
whether responses are high affinity interactions with
foreign (viral) epitopes or lower affinity interactions
involving recognition of self-antigens. We have previously
demonstrated that high frequencies of T cells directed
against the self-antigen MBP peptide 85–99 in the periph-
eral blood of patients with multiple sclerosis (MS) fail to
proliferate when stimulated with antigen but readily secrete
high levels of cytokine [40]. Given that T cell responses
directed against MAGE and IL-13Rα2 antigens also involve
T cells with low affinity to these self-antigens, we quanti-
fied antigen-specific responses based on cytokine secretion,
as recently described in a phase I study of patients with
MS [41]. We quantified cytokine production by ELISA, de-
fining a positive T cell response for each patient as the
amounts of IFN-γ or IL-5 that were > 50 pg/mL and two
standard deviations above the mean cytokine levels
secreted after stimulation of cells from that patient with
negative control MBP peptide. The mean cut-off for a posi-
tive cytokine response based on cytokine induced by
stimulation with control MBP peptide was 895 pg/ml
Figure 1 Global T cell cytokine profiles among patients with CNS tumors and healthy controls. (a) The geometric mean values and
standard deviation of IFN-γ and IL-5 levels from all T cell cultures generated with anti-CD3 mAb among the four groups examined are presented.
Modest decreases in the amount of secreted IFN-γ are seen among all patients with CNS tumors when compared to healthy subjects, while a
significant elevation of IL-5 levels is seen only in recurrent GBM patients. (b) The ratios of IFN-γ to IL-5 for all primary T cell responses are shown
for each cohort. There was no difference in this ratio comparing patients with meningiomas to healthy subjects, but patients with primary and
recurrent GBM patients exhibited significantly lower ratios compared to both healthy subjects and meningioma patients.
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and IL-5 among healthy subjects, and was 123 pg/ml
(range: 0–286) and 312 pg/ml (range: 59–1347) for IFN-γ
and IL-5 among GBM patients. Use of a traditional IFN-γ
ELISPOT assay, in which quantification of spots can at
times be ambiguous, confirmed that memory T cell
responses could be detected with these peptides in patients
with primary GBMs, as peptide specific cytokine production
could be detected with 48 hours of culture (Figure 2).
T cells responding to all five peptides examined among
healthy subjects exhibited a predominant Th1 response
(high IFN-γ and low IL-5 secretion) (Figure 3). In
marked contrast, the majority of peptide-specific T cell
responses among both primary and recurrent GBM











The location of five candidate glioma-associated epitopes are depicted within
the MAGE-A3 and IL-13Rα2 protein sequences. The location of documented
melanoma-associated CTL epitopes are italicized within the three candidate
MAGE-A3 epitopes and one of the IL-13Rα2 peptides. The location of
previously described HLA class II-restricted melanoma epitopes (MAGE-
A3121-134 and MAGE-A3146-160) are shown for comparative purposes.
Amino acid differences in the candidate glioma-associated epitopes
from the MAGE-A3 sequence are highlighted in bold.secretion). Frequencies of response to the individual
peptides were most prevalent among healthy subjects
and patients with primary GBMs, both in terms of the
number of subjects responding to a given peptide and
the number of positive lines. Responses in one or a few
subjects did not dominate among any of the cohorts
examined; at least half of the subjects (in some cases
all) in each cohort responded to all of the epitopes
tested (Table 3). Patients with meningiomas generally
had less frequent responses, though strong responses
could be detected against both MAGE-A3 and IL-
13Rα peptides. Mean IFN-γ/IL-5 ratios were signifi-
cantly lower (p<0.05) for patients with primary GMBs
(geometric means for MAGE-A3112-127, MAGE-A3121-136,
MAGE-A3143-160, IL13Rα2341-355, and IL-13Rα2351-365 were
0.2, 0.1, 0.3, 0.3, 0.3, respectively) relative to healthy subjects
(geometric means were 4.9, 8.1, 4.3, 1.6, 2.0, respectively) in
response to all of the epitopes (Figure 4). The Th2 bias was
even more profound among patients with recurrent GBMs
(geometric means for MAGE-A3112-127, MAGE-A3121-136,
MAGE-A3143-160, IL13Rα2341-355, and IL-13Ra2351-365
were 0.04, 0.06, 0.4, 0.02, 0.05), and was significantly lower
than that of patients with primary GBMs for the MAGE-
A3143-160 and IL-13Rα2351-365 epitopes (P<0.05).Discussion
Cytokines, while not directly cytolytic to tumor cells,
can create strong negative pressure on tumor cell
survival. Noteworthy are observations that mice unable
to secrete or respond to the cytokine IFN-γ are more
susceptible to chemically-induced and spontaneous tumors
[42], and that in humans Th1 responses among tumor infil-
trating lymphocytes are associated with favorable clinical
outcome [43]. Thus, secretion of IFN- a cytokine that
Patient 1 Patient 2 Patient 3
Figure 2 Memory T cell responses against GBM peptide antigens detected by ELISPOT. The MAGE-A3 peptides (MAGE-A3112-127, MAGE-
A3121-136, and MAGE-A3143-160 were dissolved in DMSO in equimolar amounts (peptide pool I) while the IL13Rα2 peptides IL13Rα2341-355 and IL-
13Rα2351-365 were similarly dissolved together (peptide pool II) and used to stimulate freshly isolated PBMCs from 3 patients with primary GBMs.
Significant (p < 0.05) responses to both peptide pools were detected in all patients. Mean + SD are presented.
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involved in tumor immunity. By contrast, Th2 cells secrete
cytokines such as IL-4, IL-5, and IL-13, and the characteris-
tic cytokines produced by Th1 and Th2 cells are mutually
inhibitory for the differentiation and effector functions ofFigure 3 T cell cytokine profiles to each peptide among each cohort.
positive T cell response, defined as greater than 50 pg/ml and two standar
of cells with negative control MBP peptide for each subject. The mean cut-
stimulation with control MBP peptide was 895 pg/ml (range: 13–1298) and
and was 123 pg/ml (range: 0–286) and 312 pg/ml (range: 59–1347) for IFNthe reciprocal T cell phenotype. Accordingly, it is prudent
to evaluate the Th1/Th2 balance in order to predict the
efficacy of helper T cells directed against a tumor. Several
reports using both animal models and human tumor speci-
mens have investigated the Th1/2 cytokine balance inEach symbol represents the IFN-γ and IL-5 cytokine levels for a
d deviations above the mean cytokine levels secreted after stimulation
off for a positive cytokine response based on cytokine induced by
314 pg/ml (range: 72–852) for IFN-γ and IL-5 among healthy subjects,
-γ and IL-5 among GBM patients.
Figure 4 Th1/2 ratios of T cell responses to each peptide among each cohort. The ratio of IFN-γ to IL-5 for each primary T cell response
presented in Figure 3 is presented. Patients with primary GBMs had significantly lower ratios compared to healthy subjects for every antigen examined.
Patients with recurrent GBMs had significantly lower ratios compared to patients with primary GBMs in response to the MAGE-A3143-160 and IL-13Rα2351-365
epitopes (p<0.05).
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However, none of these investigations characterized the T
cell-derived, tumor-specific cytokine balance.
In this study we evaluated T helper cell responses
against a panel of putative HLA class II-restricted
peptides derived from glioma-associated tumor antigens.
To our knowledge this is first study to demonstrate
glioma-associated, class II-restricted epitopes and to
reveal a profound Th2 bias among glioma-specific T
helper cells. Th2-skewed immunity specific to carbioem-
bryonic antigen has similarly been observed in patients
with pancreatic cancer [44]. We further observed that
the Th2 bias in GBM patients is augmented among
patients with recurrent GBMs due to enhanced secretion
of the Th2 cytokine IL-5. Suppression of Th1 immunityis similarly observed in colorectal cancer patients at a
relatively early stage of the disease while increased Th2
immunity appears during terminal stages of disease [45],
suggesting that blunting of Th1 responses occurs prior to,
not concomitant with, Th2 deviation of tumor-specific
immunity. In contrast to responses detected in patients
with malignant GBMs, circulating T helper cells directed
against the same epitopes were readily detected among
healthy subjects with a protective Th1 bias at comparable
frequencies.
Conclusions
Our findings suggest that both primary and recurrent
GBM patients are unlikely to have the capacity to favor-
ably respond to immunization against tumor antigens
Table 3 Frequencies of response among subjects to the candidate glioma-associated T helper cell epitopes
MAGE-A3112-127 MAGE-A3121-136 MAGE-A3143-160 IL-13Rα2341-355 IL-13Rα2351-365
Primary GBM 1 ++ ++++ + +++
Primary GBM 2 ++ ++ +++ ++ ++
Primary GBM 3 ++ ++++ + +++++ ++
Primary GBM 4 + ++ + +++
Primary GBM 5 +++++ ++++ + ++ +
Primary GBM 6 ++ ++ + ++
Primary GBM 7 +++ ++++ ++ +++ +++
Primary GBM 8 ++++ ++ +++++ ++++ +++++
Recurrent GBM 1 + ++ + ++ ++
Recurrent GBM 2 +
Recurrent GBM 3 ++ + + +
Recurrent GBM 4 ++ + +





Meningioma 5 +++ ++ ++
Meningioma 6 + + + + ++++++
Meningioma 7 +
Healthy Subject 1 +++ +++ +++ +
Healthy Subject 2 + +++ +
Healthy Subject 3 ++ +++ +
Healthy Subject 4 ++ + +++++ + +++++
Healthy Subject 5 + + ++ ++++ ++
Healthy Subject 6 + + + ++
Cytokine production was quantified by ELISA, defining a positive T cell response for each patient as the amounts of IFN-γ or IL-5 that were > 50 pg/mL and two
standard deviations above the mean cytokine levels secreted after stimulation of cells from that patient with negative control MBP peptide. A total of 6 primary T
cell responses were measured for each subject against each peptide. (+) symbols indicate the precise number of positive wells among six for each peptide.
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ability to promote Th1 immunity. Indeed, suboptimal
vaccination could even enhance the immunosuppressive
status of patients, as recently demonstrated when HLA
class II-restricted peptide vaccination induced regulatory
T cells with potential to exacerbate the immunosuppres-
sive state in the patients [46]. In another recent clinical
trial conducted in melanoma patients that involved
multiple HLA class II-restricted peptides from MAGE
and melanocytic differentiation antigen, vaccine-induced
T helper cell responses were induced in a majority of
the patients (81%), yet beneficial clinical responses were
observed in only two out of 17 patients [47].
Studies have demonstrated that resection of tumor or
achievement of disease free status can restore Th1
immunity in patients with malignant diseases such as
malignant melanomas and renal cell carcinomas [48,49].This suggests that successful resection of gliomas may
reverse an unfavorable background that promotes Th2
bias in these patients, and may represent an ideal time
at which to administer a therapeutic vaccine comprised
of the HLA class II-restricted glioma-associated antigens
that we have defined. Formulation of our GBM peptide
antigens with TLR agonists, in particular the TLR9
agonist CpG, could be used to further reverse the Th2
bias directed against these antigens as well as ameliorate
the suppressive activity associated with regulatory T cells
directed against the same antigens [50-54]. Moreover,
the antigens that we have defined may be applicable
to vaccination of patients with melanoma, given that
MAGE antigens are frequently over-expressed among
melanomas, and functional evidence of T helper cell
recognition of antigens shared by melanoma and glioma
cells [55].
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